Quantcast
Channel: Knobbe Martens Intellectual Property Law - IP Strategy

Barriers To Entry: The Patent System's Silver Bullet For Medical Companies

$
0
0

Partner Jarom Kesler authored "Barriers To Entry: The Patent System's Silver Bullet For Medical Companies" which was published on the Diagnotics World News website. 

Excerpt: Often significant and unique barriers to entry confront medical device companies. There are critical deadlines that need to be met, significant funding that needs to be found, regulatory hurdles, market penetration roadblocks, safety concerns, and the list goes on. One of the larger hurdles is market-controlling competitors, particularly competitors that control a market with dated technology. But I have a silver bullet to help my clients overcome this and many other challenges—patents.

Read the full article here >> 

 

Associated Practice Area 

Associated Industry Group 

Type 

Publications
Friday, May 17, 2019

Attorneys 

Shorter Headline Homepage

Barriers To Entry: The Patent System's Silver Bullet For Medical Companies

image

IP Strategy

Hide from Latest News


Knobbe Martens Achieves Top Rankings in Managing IP’s Guide to Leading Firms - 12 Partners Recognized as IP Stars

$
0
0

Knobbe Martens again ranked as one of the top intellectual property law firms in the country by Managing Intellectual Property (Managing IP).

Managing IP’s recently published IP STARS, the leading specialist guide to IP firms and attorneys worldwide, which recognizes Knobbe Martens for its top-tier national Life Sciences and Patent Prosecution practices, as well as its leading Patent Contentious, PTAB Litigation, Trademark Contentious, and Trademark Prosecution practices.

In California, the firm is “highly recommended” in Patent Contentious, Patent Prosecution, Trademark Contentious, and Trademark Prosecution, and also recommended for Copyright and Related Rights. The firm’s IP practice is also recommended in Washington, where it has a Seattle office.

Additionally, 12 Knobbe Martens partners are  recognized in the guide as “IP Stars.”  The IP STAR litigators are Jon Gurka, Stephen Jensen, Christy Lea, Joseph Re, John Sganga, and William Zimmerman.  The IP STAR practitioners are Maria Anderson, Sabing Lee, Salima Merani, Ph.D., Susan Natland, Robert Roby, and Gerard von Hoffmann.

Susan Natland and Salima Merani, Ph.D., were also selected on MIP’s “Top 250 Women in IP” list. This list recognizes the leading female IP practitioners who have performed exceptionally for their clients and firms in the past year. The selection process also factors in activities in the IP community and corporate social responsibility initiatives.

The IP STARS survey, the most comprehensive analysis of its kind, covers 70 countries and ranks leading law firms by nation. The research looks at a firm’s strength in the practice area concerned and client outcomes delivered. IP Stars are selected based on available information, including market feedback and is a selective process. To learn more about Managing IP’s analysis of the firm’s national and regional rankings, click here.

 

 

Type 

News
Monday, May 20, 2019

Shorter Headline Homepage

Firm Achieves Top Rankings in MIP’s Guide to Leading Firms - 12 Partners Named IP Stars

image

IP Strategy

Hide from Latest News

Andrew E. Morrell

$
0
0

Education 

Telephone 

949-760-0404

Office Location(s) 

Professional Profile 

Andrew represents clients in intellectual property matters—principally for clients in the pharmaceutical, chemical, and biotechnology industries.  His practice is varied, though it often allows him to utilize the technical training he received while earning his Ph.D. in Medicinal Chemistry & Molecular Pharmacology for research on the synthesis and biological evaluation of small molecule therapeutics. 

Andrew regularly litigates matters brought under the Hatch-Waxman Act and counsels clients as they prepare their Abbreviated New Drug Applications (ANDAs).  He also represents both patent owners and petitioners in administrative proceedings before the Patent Trial and Appeal Board (PTAB).  And when he isn’t preparing for trial, Andrew helps clients obtain patents, analyzes third-party patents, conducts due diligence studies, and prepares opinions on patent-related issues.

In his free time, Andrew enjoys hiking, camping, and mastering the art of home brewing.

Clerk Experience
From 2017 to 2019, Andrew served as a judicial law clerk for the Honorable Pauline Newman of the U.S. Court of Appeals for the Federal Circuit­­—the appellate court hearing all patent appeals coming out of district courts, the United States Patent and Trademark Office, and the ITC.

 

Cases, Articles, Speeches & Seminars 

PUBLICATIONS

  • N. Nenortas, M. Cinelli, A. Morrell, M. Cushman, & T. Shapiro, “Activity of Aromathecins Against African Trypanosomes,” Antimicrob. Agents Chemother.2018, 62, e00786–18.
  • M. Conda-Sheridan, P. V. Narasimha Reddy, A. Morrell, B. T. Cobb, C. Marchand, K. Agama, A. Chergui, A. Renaud, A. G. Stephen, L. K. Bindu, Y. Pommier, & M. Cushman, “Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1),” J. Med. Chem.2013, 56, 182-200.
  • L. Chen, M. Conda-Sheridan, P. V. N. Reddy, A. Morrell, E.-J. Park, T. P. Kondratyuk, J. M. Pezzuto, R. B. van Breemen, & M. Cushman, “Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents,” J. Med. Chem.2012, 55, 5965–81.
  • T. X. Nguyen, A. Morrell, M. Conda-Sheridan, C. Marchand, K. Agama, A. Bermingham, A. G. Stephen, A. Chergui, A. Naumova, R. Fisher, B. O’Keefe, Y. Pommier, & M. Cushman, “Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)−Topoisomerase I (Top1) Inhibitors,” J. Med. Chem.2012, 55, 4457–78.
  • E. Kiselev, S. DeGuire, A. Morrell, K. Agama, T. S. Dexheimer, Y. Pommier, & M. Cushman, “7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer Agents,” J. Med. Chem.2011, 54, 6106–16.
  • K. E. Peterson, M. A. Cinelli, A. E. Morrell, A. Mehta, T. S. Dexheimer, K. Agama, S. Antony, Y. Pommier, & M. Cushman, “Alcohol-, Diol-, and Carbohydrate-Substituted Indenoisoquinolines as Topoisomerase I Inhibitors: Investigating the Relationships Involving Stereochemistry, Hydrogen Bonding, and Biological Activity,” J. Med. Chem.2011, 54, 4937–53.
  • E.-J. Park, T. P. Kondratyuk, A. Morrell, E. Kiselev, M. Conda-Sheridan, M. Cushman, S. Ahn, Y. Cho, J. J. White, R. B. van Breemen, & J. M. Pezzuto, “Induction of Retinoid X Receptor Activity and Consequent Up-regulation of p21WAF1/CIP1 by Indenoisoquinolines  in MCF7 Cells,” Cancer Prev. Res.2011, 4, 592–607.
  • L. Marler, M. Conda-Sheridan, M. A. Cinelli, A. E. Morrell, M. Cushman, L. Chen, K. Huang, R. van Breemen, & J. M. Pezzuto, “Cancer Chemopreventive Potential of Aromathecins and Phenazines, Novel Natural Product Derivatives,” Anticancer Res.2010, 30, 4873–82.
  • M. A. Cinelli, A. E. Morrell, T. S. Dexheimer, K. Agama, S. Agrawal, Y. Pommier, & M. Cushman, “The Structure–activity Relationships of A-Ring-substituted Aromathecin Topoisomerase I Inhibitors Strongly Support a Camptothecin-like Binding Mode,” Bioorg. Med. Chem.2010, 18, 5535–52.
  • R. P. Bakshi, D. Sang, A. Morrell, M. Cushman, & T. A. Shapiro, “Activity of Indenoisoquinolines against African Trypanosomes,” Antimicrob. Agents Chemother.2009, 53, 123–28.
  • M. A. Cinelli, A. Morrell, T. S. Dexheimer, E. S. Scher, Y. Pommier, & M. Cushman, “Design, Synthesis, and Biological Evaluation of 14-Substituted Aromathecins as Topoisomerase I Inhibitors,” J. Med. Chem.2008, 51, 4609–19.
  • S. Antony, K. K. Agama, Z.-H. Miao, K. Takagi, M. H. Wright, A. I. Robles, L. Varticovski, M. Nagarajan, A. Morrell, M., Cushman, & Y. Pommier,  “Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance,” Cancer Res.2007, 67, 10397–405.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors: A Systematic Study and Optimization,” J. Med. Chem.2007, 50, 4419–30.
  • A. Morrell, M. Placzek, S. Parmley, S. Antony, T. Dexheimer, Y. Pommier & M. Cushman, “Optimization of the Indenone Ring of Indenoisoquinoline Topoisomerase I Inhibitors,” J. Med. Chem.2007, 50, 4388–404.
  • A. Morrell, M. S. Placzek, J. D. Steffen, S. Antony, K. Agama, Y. Pommier, & M. Cushman, “Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell Cultures,” J. Med. Chem.2007, 50, 2040–48.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I Inhibitor,” J. Med. Chem.2006, 49, 7740–53.
  • M. Nagarajan, A. Morrell, A. Ioanoviciu, S. Antony, G. Kohlhagen. M. Hollingshead, Y. Pommier, & M. Cushman, “Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles,” J. Med. Chem.2006, 49, 6283–89.
  • X. Xiao, A. Morrell, P. E. Fanwick, & M. Cushman, “On the Mechanism of Conversion of 4-Carboxy-3,4-dihydro-3-phenyl-1(2H)-isoquinolones to Indeno[1,2-c]isoquinolines by Thionyl Chloride,” Tetrahedron2006, 62, 9705–12.
  • M. Nagarajan, A. Morrell, S. Antony, G. Kohlhagen, K. Agama, Y. Pommier, P. A. Ragazzon, N. C. Garbett, J. B. Chaires, M. Hollingshead, & M. Cushman, “Synthesis and Biological Evaluation of Bisindenoisoquinolines as Topoisomerase I Inhibitors,” J. Med. Chem.2006, 49, 5129–40.
  • S. Antony, K. K. Agama, Z.-H. Miao, M. Hollingshead, S. L. Holbeck, M. H. Wright, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, & Y. Pommier, “Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity,” Mol. Pharmacol.2006, 70, 1109–20.
  • A. Morrell, M. Jayaraman, M. Nagarajan, B. M. Fox, M. R. Meckley, A. Ioanoviciu, Y. Pommier, S. Antony, M. Hollingshead, & M. Cushman, “Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Using a Hollow Fiber Assay,” Bioorg. Med. Chem. Lett.2006, 16, 4395–99.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier & M. Cushman, “Synthesis of Benz[d]indeno[1,2-b]pyran-5,11-diones: Versatile Intermediates for the Design and Synthesis of Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett.2006, 16, 1846–49.
  • Muthukaman Nagarajan, Andrew Morrell, Brian C. Fort, Marintha Rae Meckley, Smitha Antony, Glenda Kohlhagen, Yves Pommier, & Mark Cushman, “Synthesis and Anticancer Activity of Simplified Indenoisoquinoline Topoisomerase I Inhibitors Lacking Substituents on the Aromatic Rings,” J. Med. Chem.2004, 47(23), 5651–61.
  • A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Synthesis of Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett.2004, 14, 3659–63.

 

PATENTS

  • U.S. 9,388,211: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” July 12, 2016
  • U.S. 9,217,010: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” December 22, 2015
  • U.S. 9,034,870: “Azaindenoisoquinolines Topoisomerase I Inhibitors,” May 19, 2015
  • U.S. 8,829,022: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” September 9, 2014
  • U.S. 8,686,146: “Azaindenoisoquinolines Topoisomerase I Inhibitors,” April 1, 2014
  • U.S. 8,053,443: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” November 8, 2011
  • U.S. 7,495,100: “Synthesis of Indenoisoquinolines,” February 24, 2009
  • Japanese Patent No. 5890806: “N-Substituted Indenoisoquinolines and Their Synthesis,” November 15, 2013
  • Japanese Patent No. 5567157: “N-Substituted Indenoisoquinolines and Their Synthesis,” June 27, 2014
  • Japanese Patent No. 5412113: “N-Substituted Indenoisoquinolines and Their Synthesis,” November 15, 2013
  • European Patent No. 1960366: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” July 20, 2016
  • Canadian Patent No. 2629530: “N-Substituted Indenoisoquinolines and Syntheses Thereof,” July 8, 2014

 

Andrew

Lastname 

Morrell

Photo 

IP Strategy

Position 

Email 

andrew.morrell@knobbe.com

Start Date 

Tuesday, May 28, 2019

Knobbe Martens Recognized for Top IP Performance by The Legal 500

$
0
0

Knobbe Martens is pleased to announce that it has once again received top recognition in The Legal 500 “United States Guide.” The annual publication, which recognizes leading law firms and attorneys worldwide, noted that the “intellectual property giant” “impresses with 'a deep bench of technical and legal experts.'” It commended the firm’s performance in four areas of IP, including:

Patent Licensing

Joseph Cianfrani
Jason Jardine
Salima Merani
Rabi Narula
Terry Tullis
Gerard von Hoffmann
Bryan Wahl

Patent Litigation

Joseph Cianfrani
Jon Gurka
Christy Lea
William Zimmerman

Patent Prosecution (including re-examination and post-grant proceedings)

Mark Abumeri
Michael Fuller
Mark Gallagher
Steven Nataupsky
John Paik
Ed Schlatter
Kerry Taylor
Gerard von Hoffmann
William Zimmermann

Trademarks: Non-Contentious (including prosecution, portfolio management and licensing)

Susan Natland
Diane Reed
Jeff Van Hoosear

The Legal 500 rankings, which are designed to connect corporate counsel with the right advisors, are based on feedback from 250,000 in-house peers, as well as independent assessments of law firm deals and other matters. The full list of rankings can be viewed here.

About Knobbe Martens

Consistently ranked among the top intellectual property firms in the nation and worldwide, Knobbe Martens has close to 275 lawyers and scientists nationwide and dedicates its practice to all aspects of intellectual property and technology law, including litigation. Knobbe Martens serves a diverse group of clients from multinational corporations to emerging businesses of all stages. The firm is headquartered in Orange County, California, with offices in Los Angeles, New York, San Diego, San Francisco, Seattle and Washington, D.C., and enjoys an international reputation for excellence. More information about the firm can be found at www.knobbe.com.

 

Type 

News
Friday, May 31, 2019

Shorter Headline Homepage

Knobbe Martens Recognized for Top IP Performance by The Legal 500

image

IP Strategy

Hide from Latest News

Kendrick S. Hsu

$
0
0

Telephone 

949-760-0404

Office Location(s) 

Professional Profile 

Kendrick Hsu is an associate at the Orange County office. Kendrick focuses his practice on patent prosecution. Kendrick’s practice involves a variety of technologies including semiconductors, nanotechnology, MEMS, and optics.

Kendrick has a diverse educational background. Kendrick received his Bachelor’s degree in Materials Science and Engineering from University of California, Los Angeles. He also received a Master’s degree in Electrical Engineering from University of Southern California. Kendrick received his J.D. from Georgetown University Law Center in 2018.

Prior to joining the firm, Kendrick was a primary patent examiner at the USPTO where he examined all aspects of Liquid Crystal Display (LCD) devices for six years. Prior his time at the USPTO, Kendrick was a defense contractor in the Washington DC area for three years.

Additional Information 

Conversationally proficient in Mandarin.

Kendrick

Lastname 

Hsu

Photo 

IP Strategy

Position 

Email 

kendrick.hsu@knobbe.com

Start Date 

Sunday, June 2, 2019

Justin E. Culbertson, Ph.D.

$
0
0

Telephone 

202-640-6400

Office Location(s) 

Professional Profile 

Justin Culbertson is an associate at our Washington D.C. office.  His practice focuses on intellectual property law, with emphasis on patent prosecution, strategic counseling, and worldwide patent portfolio management in the chemical, pharmaceutical, and biotechnology fields.  Justin advises and counsels diverse clients, including early stage and established companies, research institutions, and investment firms on how to best develop, leverage and enforce their IP assets.  Justin has extensive experience in international patent prosecution, having prosecuted applications in over 20 jurisdictions worldwide.  In addition to advising client on IP strategy, Justin has counseled clients in licensing, due diligence, and patentability analyses. 

Prior to joining Knobbe Martens, Justin completed a J.D. at the University of Illinois College of Law where he participated in an IP clinic to help student inventors gain IP rights. He also participated in a mortgage foreclosure clinic helping families retain their homes in foreclosure. While in law school at the University of Illinois, Justin was a professor at Parkland College teaching organic chemistry.

Prior to law school, Justin earned his Ph.D. in Chemistry from the University of California, Davis. His interdisciplinary graduate research involved the design and mechanistic evaluation of small molecule inhibitors of the chorismate-utilizing enzymes. His studies helped him gain a deep understanding of small molecule synthesis, purification techniques, protein engineering and design, x-ray crystallography, and molecular biology.

Between graduate school and his undergrad, Justin spent a summer working at GlaxoSmithKline synthesizing vaccine adjuvants.

Justin is admitted in Arizona, Missouri and New York. Practice outside of those states is limited to matters and proceedings before federal courts and agencies.

 

Justin

Lastname 

Culbertson

Photo 

IP Strategy

Position 

Email 

justin.culbertson@knobbe.com

Start Date 

Wednesday, June 5, 2019

23 Knobbe Martens Partners Named “World’s Leading Patent Professionals” by Intellectual Asset Magazine

$
0
0

The newly released 2019 edition of the IAM Patent 1000 guide recognized Knobbe Martens as an industry leader for its litigation, transaction, and prosecution practices, awarding the firm a “silver” tier ranking for litigation and a “highly recommended” ranking for patent prosecution work in California. For its work in Washington State, the firm was ranked “silver” for litigation and prosecution, and was also recognized for its transactions work.

The publishers of Intellectual Asset Management (IAM) magazine remarked that Knobbe Martens “is one of the top IP boutiques not just in the United States but globally,” noting that “collaboration and quality are the firm’s key narratives.” They added that “its attorneys understand patent strategy at the deepest level and they train hard and constantly in order to maintain this; cultivating cutting-edge industry knowledge also keeps them at the top of the list for technology pioneers. Whereas many competitors tend towards one or the other, Knobbe Martens is equally strong in the high-technology and life sciences domains and has standout stars aplenty in both.”

In addition to the firm-wide recognition, 23 Knobbe Martens partners were named to the list of “The World’s Leading Patent Practitioners 2019”:

Transactions

Adeel Akhtar, Maria Anderson, Michael Fuller, Salima Merani, Ph.D., Kimberly Miller, Ph.D., Mauricio Uribe, and Gerard von Hoffmann

Prosecution

Adeel Akhtar, Maria Anderson, Mark Benedict, Ph.D., John Carson, Michael Fuller, John King, Eli Loots, Ph.D., Joseph Mallon, Ph.D., Salima Merani, Ph.D., Kimberly Miller, Ph.D., Joseph Reisman, Ph.D., Ron Schoenbaum, Melanie Seelig, Mauricio Uribe, and Gerard von Hoffmann

Litigation

Joseph Cianfrani, Jon Gurka, Irfan Lateef, Carol Pitzel Cruz, Joseph Re, John Sganga, Kerry Taylor, and Karen Vogel Weil

The IAM Patent 1000 rankings are based on five months of research and more than 1,800 interviews with attorneys and in-house counsel to gather market intelligence on the leading players in the field. The IAM Patent 1000 identifies the leading law firms in the market based on the depth of expertise, market presence and the level of work on which they are typically engaged. To view the full 2019 guide, click here.

About Knobbe Martens

Consistently ranked among the top intellectual property firms in the nation and worldwide, Knobbe Martens has close to 275 lawyers and scientists nationwide and dedicates its practice to all aspects of intellectual property and technology law, including litigation. Knobbe Martens serves a diverse group of clients from multinational corporations to emerging businesses of all stages. The firm is headquartered in Orange County, California, with offices in Los Angeles, New York, San Diego, San Francisco, Seattle and Washington, D.C., and enjoys an international reputation for excellence. More information about the firm can be found at www.knobbe.com.

 

Type 

News
Thursday, June 6, 2019

Contact 

Nicholas Gaffney 415-732-7801

Shorter Headline Homepage

23 Partners Named “World’s Leading Patent Professionals” by IAM

image

IP Strategy

Hide from Latest News

PTAB’s Characterization Of Petitioner’s Argument Did Not Introduce New Theory Of Invalidity

$
0
0

ARTHREX, INC. V. SMITH & NEPHEW ET AL.

Before Dyk, Chen, and Stoll.  Appeal from the U.S. Patent and Trademark Office

Summary:  The Board’s invalidity decision does not need to track the exact wording in the IPR petition so long as the Board’s characterization of the invalidity theory is consistent with the theory presented in the petition.

Smith & Nephew filed an IPR petition challenging a patent owned by Arthrex.  In the petition, Smith & Nephew argued that a POSITA would have combined two references because the combined feature was made using a “well-known technique [whose use] would have been a simple design choice.”  The petition relied on a reference passage describing the claimed technique as well as describing a second technique in the alternative.  The Board agreed with Smith & Nephew and pointed to the same reference passage, but the Board characterized the first technique as the “preferred option.”  The Federal Circuit warned that the PTAB may not change invalidity theories mid-stream without giving respondents an opportunity to argue under the new theory.  But here the Federal Circuit determined that Board did not change the invalidity theory presented in the petition.  Although Smith & Nephew did not characterize the claimed technique as the “preferred option,” this did not raise a new issue or theory of invalidity, because (1) the Board relied on the same portion of the reference as the petition, (2) the Board ruled on the same combination of features as presented in the petition, and (3) the Board “ruled on the same theory of obviousness presented in the petition”—that the combination was a “simple design choice.”  Thus, “the mere fact that the Board did not use the exact language of the petition” did not result in an APA violation under existing law.
 

Associated Practice Area 

Associated Industry Group 

Type 

Resources
Wednesday, August 21, 2019

Shorter Headline Homepage

PTAB’s Characterization Of Petitioner’s Argument Did Not Introduce New Theory Of Invalidity

image

IP Strategy

Hide from Latest News


Sunyong Tang

$
0
0

Office Location(s) 

Professional Profile 

Dr. Tang has extensive technical experience in various biotech fields, including molecular biology, genetics, microbiology, virology, and cell biology.

Dr. Tang was born and educated in China, and he is fluent in both Chinese and English. As the president of the San Diego Chinese Attorneys Association, he is actively involved in serving the community. 

 

Professional Memberships 

President, San Diego Chinese Attorneys Association, 2019-current

Industry Experience 

Sunyong

Lastname 

Tang

Photo 

IP Strategy

Position 

Email 

sunyong.tang@knobbe.com

Start Date 

Thursday, August 29, 2019